Resistance to imatinib involving Bcr-Abl independent activation of Erk1/2

Flavia Cunha Vasconcelos [1], Danielle Cardoso da Silva [2], Miguel Angelo Moreira [3], Raquel Ciuvaschi Maia [1]

1- Laboratório de Hemato-Oncologia Celular e Molecular, Programa de Hemato-Oncologia Molecular, INCA, Rio de Janeiro, Brasil. E-mail: vasconcelosfc@hotmail.com. Phone: +5521 980837887

2- Programa de Pós-Graduação em Oncologia, Instituto Nacional de Câncer (INCA), Rio de Janeiro, Brasil

3- Coordenação de Pesquisa - Divisão de Genética - INCA, Rio de Janeiro, Brasil

Tyrosine kinase inhibitor (TKI)-based therapy has dramatically enhanced chronic myeloid leukemia (LMC) panorama of treatment response, disease progression and overall survival. In spite of its effectiveness and the development of more potent TKIs, resistance to treatment is still an issue. The recurrence of patients whose resistance is unrelated to BCR-ABL mutations points out to the importance of studying other resistance mechanisms. In this context, our group developed an imatinib (IM)-resistant cell line named K-IM through culturing K562 cells in gradually increasing IM concentrations. Since this cell line harbors no BCR-ABL kinase domain mutation, it is a perfect model for the study of Bcr-Abl unrelated resistance mechanisms. K-IM cells displayed an increase in *BCR-ABL* mRNA levels, but neither an increase in Bcr-Abl activity nor an impaired inhibition by IM were observed. Since ABC transporters are determinants for the multidrug resistance phenotype, P-glycoprotein and breast cancer resistance protein activity was evaluated, however, K-IM cells showed no transporter activity. Another important mechanism is the deregulation of apoptosis pathways and the inhibitor of apoptosis proteins XIAP and survivin which have been extensively studied as putative targets for cancer treatment. K-IM cells presented mRNA levels of XIAP similar to its parental cell line K562 and higher mRNA levels of survivin. Protein analysis confirmed an increase in survivin expression, suggesting that this protein could contribute to the cell line's resistance. The search for signaling pathways that could promote survivin overexpression led to the observation of higher phosphorylation levels of Erk 1/2 that persisted even during Bcr-Abl inhibition in the resistant cell line K-IM. This suggests that MAPK/Erk participates in a Bcr-Abl-independent resistance mechanism. There was a reduction in survivin levels after IM treatment, indicating its regulation is dependent on Bcr-Abl and not MAPK/Erk. One of the proteins that could evoke MAPK/Erk activation is the Shp2 phosphatase that interacts with adaptor proteins leading to Ras activation. However, IM treatment also impaired Shp2 phosphorylation, suggesting it is not the responsible mechanism for MAPK/Erk activation. Our data suggests that different resistance mechanisms that promote resistance may occur simultaneously and that K-IM cell line is an intriguing model for the study of resistance mechanisms and putative drug targets.



Figure 1: Cellular response to tyrosine kinase inhibitors. K562 and K-IM cell lines were incubated with different concentrations of imatinib (0.5 to 5.0 μM) **(A)** or dasatinib (2 to 200 nM) **(B)** for 72 hours and cell viability was assessed using the MTT assay. Data corresponds to 3 independent experiments bars represent standard error. Statistical analysis was performed using the two-way ANOVA test with Bonferroni post-test in which * corresponds to p<0,05; ** corresponds to p<0,01 and *** corresponds to p<0,001.



Figure 2: Cell death induction by imatinib. K562 and K-IM cell lines were treated with 1 or 5 μM imatinib or the vehicle DMSO for 24, 48 or 72 hours. Cell death induction was assessed by annexin V and propidium iodide. Statistical analysis was performed using the one-way ANOVA test with Dunnett post-test in which * corresponds to p<0,05 and *** corresponds to p<0,001.



Figure 3: Cell cycle analysis after imatinib treatment. (A) Exemple of the selection strategies of the cells analysed for cell cycle distribution. K562 **(B)** and K-IM **(C)** cell lines were treated with 1 or 5 μM imatinib or the vehicle DMSO for 24 or 48 hours. **(D)** Percentages of cells in each cell cycle phase is shown in the graphs.



Figure 4: Cell growth evaluation. K562 (A) and K-IM (B) cells were treated with 1 or 5 μM imatinib or the vehicle DMSO and cells were counted using the tripan the tripean blue exclusion method every 24 hours for 6 days. Data corresponds to two independent experiments and bars represente standard deviation.



Figure 5: Evaluation of efflux transport proteins. P-glycoprotein (Pgp) and breast cancer resistance protein (BCRP) activity was evaluated. Cells were incubated with the fluorescent substrate Rhodamine 123 (Rho) in the presence or absence of the Pgp modulator verapamil (VRP) and analized in the flow cytometer for Pgp activity. Cells were incubated with the fluorescent substrate Pheophorbide A (PhA) in the presence or absence of the BCRP modulator Fumitremorgin C (FTC) and analized in the flow cytometer for BCRP activity. B) K562 and K-IM cells were incubated with anti-Pgp antibody conjugated to ficoeritrin and analyzed in the flow cytometer.



Figure 6: Apoptosis inhibitor proteins. A) *BIRC 4* (XIAP) and *BIRC 5* (survivin) mRNA levels were assessed using RT-qPCR. β-glucuronidase (*GUSB*) gene was used as endogenous control. **B)** Survivin protein levels were assessed by western blot and HSC70 protein was used as control. **C)** K562 and K-IM cell lines were treated with 1 or 5 μM imatinib or the vehicle DMSO for 24 hours and survivin protein levels were assessed using western blot. HSC70 protein was used as control.

Figure 7: Evaluation of Bcr-Abl status: A) mRNA levels were analyzed using RT-qPCR in the K-IM cell line relative to K562 cell line. β-glucuronidase (GUSB) gene was used as endogenous control. **B)** Bcr-Abl activity was indirectly evaluated thourgh the CRKL phosphorylation levels, total CRKL and HSC70 protein levels were evaluated as control. **C)** For the assessment of Bcr-Abl inhibition by imatinib treatment, K562 and K-IM cells were treated with 1 or 5 μM of imatinib or the vehicle DMSO for 24 hours. The protein content and phosphorylation levels of CRKL protein were assessed using Western Blot. HSC70 protein was used as sample loading control.



Figure 8: ERK1/2 proteins evaluation. A) ERK1/2 proteins total and phosphorylated levels were evaluated in K562 and K-IM cell lines. **B)** K562 and K-IM cell lines were treated with 1 or 5 μM imatinib or the vehicle DMSO for 24 hours and ERK1/2 proteins total and phosphorylated levels were assessed using western blot. HSC70 protein was used as loading protein control.



Figure 9: Shp2 protein evaluation. A) Shp2 total and phosphorylated protein levels were evaluated in K562 and K-IM cell lines. **B)** K562 and K-IM cell lines were treated with 1 or 5 μM imatinib or the vehicle DMSO



Figure 10: MEK1/2 inhibition and cell death induction in K-IM cell line. A) K-IM cell line was treated with 1 μM imatinib (IM), 40 μM UO126, 10 μM AZD6544 (AZD) or the vehicle DMSO for 24 hours and ERK1/2protein total and phosphorylated levels were assessed using western blot. HSC70 protein was used as loading protein control. **B)** The cell death was analyzed in K-IM cell line after treatment with 1 μM IM, 40 μM UO126, 10 μM AZD6544 or the vehicle DMSO for 24 hours. **C)** Cell death representative result is shown.

Funding Support: INCA, FAPERJ, CNPq and Programa de Oncobiologia (UFRJ/Fundação do Câncer).

Projeto Gráfico: Serviço de Edição e Informação Técnico-Científica / INCA

INCA SUS MINISTÉRIO DA SAÚDE BRASIL GOVERNO FEDERAL